Search

Showing "11155" results for ""

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Non-Hodgkin's lymphoma risk increased with prolonged high HIV viral load

Two integrase inhibitors now making progress in clinical trials

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

ICAAC: Switching from Combivir to Truvada has benefits for treatment-experienced patients

High rate of resistance means azithromycin shouldn't be used to treat syphilis, warn doctors from San Francisco

Mortality falls in HIV/HCV coinfected Spaniards after the introduction of effective HIV treatment

ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat levels

Roche to share know-how in making protease inhibitors with poorest countries

Clinton Foundation secures price cuts for efavirenz, abacavir and rapid HIV tests

Evidence that non-B strains of HIV being transmitted in the UK

Immune reconstitution syndrome risk highest in those commencing HIV therapy with advanced HIV disease

HIV/HCV coinfected patients have poorer immunologic response to HIV treatment

Increase ribavirin dose for better HCV treatment response in coinfected individuals, experts argue

HAART reduces liver-related death risk, but hepatitis C infection increases risk, Italian study finds

Receive the latest HIV research and conference news

Showing "11155" results for ""

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Non-Hodgkin's lymphoma risk increased with prolonged high HIV viral load

Two integrase inhibitors now making progress in clinical trials

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

ICAAC: Switching from Combivir to Truvada has benefits for treatment-experienced patients

High rate of resistance means azithromycin shouldn't be used to treat syphilis, warn doctors from San Francisco

Mortality falls in HIV/HCV coinfected Spaniards after the introduction of effective HIV treatment

ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat levels

Roche to share know-how in making protease inhibitors with poorest countries

Clinton Foundation secures price cuts for efavirenz, abacavir and rapid HIV tests

Evidence that non-B strains of HIV being transmitted in the UK

Immune reconstitution syndrome risk highest in those commencing HIV therapy with advanced HIV disease

HIV/HCV coinfected patients have poorer immunologic response to HIV treatment

Increase ribavirin dose for better HCV treatment response in coinfected individuals, experts argue

HAART reduces liver-related death risk, but hepatitis C infection increases risk, Italian study finds

Receive the latest HIV research and conference news